31dec2019 30 covid19 cases (5 community, 25 imported)

[Potato_Wedges]

we want mass community testing centres setup like what Hongkong is doing

It will NEVER EVER happen. This is Singapore.

GDP is top priority.

 

[Kitty14]

not good...

Sent from Xiaomi REDMI NOTE 8 PRO using GAGT

 

[Kitty14]

I have let the nation down . . .

wtf

Sent from Xiaomi REDMI NOTE 8 PRO using GAGT

 

[chillzz]

With the vaccines, will have even more asymptomatic, because the vaccines still do not prevent infection or transmission, only prevents symptoms.

Unable to post link from OP

It works! Scientists have greeted with cautious optimism a press release declaring positive interim results from a coronavirus vaccine phase III trial — the first to report on the final round of human testing.

New York City-based drug company Pfizer made the announcement on 9 November. It offers the first compelling evidence that a vaccine can prevent COVID-19 — and bodes well for other COVID-19 vaccines in development. But the information released at this early stage does not answer key questions that will determine whether the Pfizer vaccine, and others like it, can prevent the most severe cases or quell the coronavirus pandemic.

“We need to see the data in the end, but that still doesn’t dampen my enthusiasm. This is fantastic,” says Florian Krammer, a virologist at Icahn School of Medicine at Mount Sinai in New York City, who is one of the trial’s more than 40,000 participants. “I hope I’m not in the placebo group.”

The vaccine, which is being co-developed by BioNTech in Mainz, Germany, consists of molecular instructions — in the form of messenger RNA — for human cells to make the coronavirus spike protein, the immune system’s key target for this type of virus. The two-dose vaccine showed promise in animal studies and early-stage clinical trials. But the only way to know whether the vaccine works is to give it to a large number of people and then follow them over weeks or months to see whether they become infected and symptomatic. These results are compared with those for a group of participants who are given a placebo.

In the press release, Pfizer and BioNTech said they had identified 94 cases of COVID-19 among 43,538 trial participants. The companies did not indicate how many of those cases were in the placebo group or among those who got the vaccine. But they said that the split of cases between the groups suggested that the vaccine was more than 90% effective at preventing disease, when measured at least one week after trial participants had received a second vaccine dose 3 weeks after the first. The trial will continue until a total of 164 COVID-19 cases are detected, so initial estimates of the vaccine’s effectiveness could change.

Although the vaccine might not turn out to be quite so effective once the trial is complete and all the data have been analysed, its effectiveness is likely to stay well above 50%, says Eric Topol, a cardiologist and director of the Scripps Research Translational Institute in La Jolla, California. This is the threshold that the US Food and Drug Administration (FDA) says is required for a coronavirus vaccine to be approved for emergency use. “I think this is an extraordinary achievement, even without many details, because there was no assurance of vaccine efficacy before we got the first read-out from a trial,” Topol says.

Questions remain

What’s missing, say Topol and other scientists, are details about the nature of the infections the vaccine can protect against — whether they are mostly mild cases of COVID-19 or also include significant numbers of moderate and severe cases. “I want to know the spectrum of disease that the vaccine prevents,” says Paul Offit, a vaccine scientist at the Children’s Hospital of Philadelphia in Pennsylvania who sits on a US Food and Drug Administration advisory committee that is set to evaluate the vaccine next month. “You’d like to see at least a handful of cases of severe disease in the placebo group,” he adds, because it would suggest that the vaccine has the potential to prevent such cases.

It’s unclear whether the vaccine can prevent people who show no or only very mild symptoms of COVID-19 from spreading the coronavirus. A transmission-blocking vaccine could accelerate the end of the pandemic. But it will be difficult to determine whether the Pfizer vaccine, or others in late-stage trials, can achieve this, says Krammer, because it would involve routinely testing trial participants. “You can’t do that with 45,000 people,” he says.

Another missing detail is how well the vaccine works in different groups of trial participants. “We don’t know yet if it works in the population that needs it most, which is elderly,” says Krammer. Because of the small number of cases it will accrue before ending, the Pfizer trial is unlikely to conclusively determine the vaccine’s efficacy in particular demographic groups, such as over-65s or African Americans, says Offit. But he adds that if the trial enrolled enough participants from such groups, it could be possible to generalize the vaccine’s probable effectiveness in them from its overall efficacy. In the press release, Pfizer and BioNTech reported that 42% of participants had “racially and ethnically diverse backgrounds”.

Lasting immunity?

One key unanswered question is how long the vaccine’s effectiveness will last. On the basis of when the trial started and previously published data on immune responses in early-stage trials, many trial participants are likely to still have high levels of protective antibodies in their blood, says Rafi Ahmed, an immunologist at Emory University in Atlanta, Georgia. “To me, the main question is what about six months later, or even three months later,” he says.

There will be a chance to answer that question if the trial continues for several more months, says Ahmed. Answers could also come from analysis of the immune responses of people who took part in early-stage trials of the Pfizer vaccine, some of whom might have been given the vaccine up to six months ago. And although little is known about the vaccine’s long-term effectiveness, that is unlikely to hold up its use, says Ahmed. “I don’t think we should say, ‘Well, I’ll only take a vaccine that protects me for five years.’ I mean, that could be crazy.”

The results are a boost for other COVID-19 vaccine candidates. That includes an mRNA vaccine being developed by Moderna, a biotechnology company in Cambridge, Massachusetts, and the US National Institute of Allergy and Infectious Diseases in Bethesda, Maryland, says Krammer. “I expect Moderna stocks will go up today.”

Shane Crotty, a vaccine immunologist at the La Jolla Institute for Immunology in California, thinks that Moderna isn’t the only developer that should celebrate Pfizer’s preliminary results. Several other candidate vaccines triggered immune responses similar to those elicited by Pfizer’s vaccine in early-stage trials, so they should work well, too.

One thing about Pfizer’s vaccine is certain: regulators will soon decide whether it’s ready for roll-out. The company said it would seek an emergency use authorization from the FDA around the third week of November, at which point half of the participants will have been followed for two months — an FDA safety requirement for COVID-19 vaccines.

And although researchers want to see the data behind Pfizer’s vaccine trial, they are prepared to accept caveats that come with them. “Right now, we need a vaccine that works,” says Krammer, even if it works for only a few months or doesn’t stop transmission. “That’s what we need in order to get half-way back to normal.”[/QUOTE]


Article says "unclear" and still need more trials and data. Well, there is still a possibility though.

 

[plasticpistola]

those taking lifts pls dun take off your masks hor damn idiot one

the other nite i kan one ** who pulled his mask down to his chin, summore he machiam like panting wtf

 

[Kitty14]

If phase3.(covid)>phase2.(covid):
phase3=**
print("go back to **")
else:
.....

hahaha

Sent from Xiaomi REDMI NOTE 8 PRO using GAGT

 

[Honeydewz]

those taking lifts pls dun take off your masks hor damn idiot one

the other nite i kan one ** who pulled his mask down to his chin, summore he machiam like panting wtf

i always reach home wash hand n leg then remove my mask

 

[yumsang]

not long ago mask wear under chin or under nose
now is hold in hand

 

[WussRedXLi]

those taking lifts pls dun take off your masks hor damn idiot one

the other nite i kan one ** who pulled his mask down to his chin, summore he machiam like panting wtf

Over at my area, easily a few dozen cases like that already since phase 2. Lost count. Majority are joggers who ended their runs or going for their runs, so...... (my area got dedicated jogging track + also a park right beside the estate).

 

[Angtehkor]

Import so many. Really is no eyes see.

 

[Darkshadows]

those taking lifts pls dun take off your masks hor damn idiot one

the other nite i kan one ** who pulled his mask down to his chin, summore he machiam like panting wtf

Haha nice one. Lift is a confined space, removing the mask inside the lift can spread more easily if the person is carrying any virus.

 

[Hamtoro]

So how many of them are CECApore

 

[kaypohmeow]

i always reach home wash hand n leg then remove my mask

Saw a few times, people took off their mask immediately after stepping out of the lift and threw into the rubbish chute in the lift lobby, cannot wait until go home then throw, tsk tsk

 

[ichinisan]

Lai liao. Can go back to double digits soon. Song bo!

 

[ChrisChamber]

Today no update at night?

 

[wheelloader]

Don't worry lah

Quite sure tomorrow onwards back to 0 community

Pappies number one!

 

[starmerck]

Don't worry lah

Quite sure tomorrow onwards back to 0 community

Pappies number one!

Focus on the zero new community cases for the past consecutive xx days hokay

 

[matchy]

wlwlsmdwl !!!!!!!!

 

[jonesftw]

https://www.moh.gov.sg/news-highlig...ly-transmitted-covid-19-infection-31decfullpr Imported cases: 25

Amongst the 25 imported cases,

2 (Cases 58828 and 58839) are Singaporeans and 3 (Cases 58819, 58820 and 58832) are Singapore Permanent Residents who returned from the UK, Indonesia and India.2 (Cases 58823 and 58831) Work Pass holders who arrived from the Philippines and India.14 are Work Permit holders who arrived from Indonesia, Bangladesh, India, Philippines and Myanmar, of whom 9 (Cases 58821, 58822, 58824, 58825, 58826, 58827, 58834, 58835 and 58836) are foreign domestic workers.1 (Case 58814) is a Dependant’s Pass holder who arrived from India.1 (Case 58830) is a Long-Term Visit Pass holder who arrived from India.1 (Case 58837) is a Short-Term Visit Pass holder who arrived from India to visit her Singaporean spouse.1 (Case 58838) is a Special Pass holder who is a crew member of a ship which arrived from Hong Kong. He had not disembarked from the ship until he was conveyed to a quarantine facility after being identified as a close contact of an overseas case.

They had all already been placed on SHN or isolated upon arrival in Singapore and were tested while serving SHN or under isolation.

 

[jonesftw]

There are 5 cases in the community today, of whom 1 is currently unlinked.

Cases 58842 and 58843

Cases 58842 and 58843 are family members of Case 58810 [1] who live in the same household. Case 58842 is a 46 year-old female Singapore Permanent Resident who works as a freelance florist at her place of residence at Ghim Moh Road. She had been identified as a close contact of Case 58810 on 29 December, and placed on home quarantine on 30 December. She developed symptoms on the same day and was conveyed to the National Centre for Infectious Diseases (NCID) in an ambulance, where she was tested. Her test result came back positive for COVID-19 infection the next day.

Case 58843 is a 14 year-old female Singapore Permanent Resident who had been identified as a close contact of Case 58810 on 29 December, and was placed on home quarantine on 30 December with Case 58842. She was conveyed to NCID with Case 58842 on 30 December, and tested. Her test result came back positive for COVID-19 infection on 31 December, and she also started to develop symptoms on the same day. She is a student of Raffles Girls’ School, and her last day in school was on 23 December.

Case 58817

Case 58817 is a 55 year-old male Singaporean who works as a Harbour Pilot at PSA Marine Pte Ltd (70 West Coast Ferry Road). His work entails going onboard vessels to navigate them through congested waters.

He is asymptomatic, and was detected from our Rostered Routine Testing (RRT) of workers in the construction, marine and process sectors on 28 December. His test came back positive on 30 December and he was conveyed to NCID in an ambulance. His serological test result has come back negative, indicating that this is likely a current infection. His earlier tests from RRT – the last being on 12 December – had been negative for COVID-19 infection.

He stays at Marine Crescent and often visited his relatives who stay in a neighbouring block. It was revealed that on 13 December, he had visited Parkway Parade with 7 other individuals. Investigations are ongoing to assess if there had been any breach of the relevant prevailing safe management measures.

Cases 58840 and 58841

Case 58840 is a 79 year-old female Singaporean who is a retiree and Case 58841 is a 50 year-old male Singaporean who is currently unemployed. They are relatives of Case 58817, and reside at Marine Crescent. On 28 December, both cases developed acute respiratory infection symptoms but did not seek medical treatment. On 30 December, they were both placed on quarantine as they had been identified as close contacts of Case 58817. As they were already symptomatic, they were conveyed to NCID in ambulances, and subsequently tested positive for COVID-19 infection.

Epidemiological investigations are ongoing. In the meantime, all the identified close contacts of the cases, including their family members and co-workers, have been isolated and placed on quarantine, and will be tested at the start and end of their quarantine period so that we can detect asymptomatic cases. We will also conduct serological tests for the close contacts to determine if the case could have been infected by them.
https://www.moh.gov.sg/news-highlig...ly-transmitted-covid-19-infection-31decfullpr